ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Genomic Surveillance of SARS-CoV-2 in Ibadan, Oyo State, Nigeria.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOyo State, Nigeria, reported its first coronavirus disease 2019 (COVID-19) case on 21 March 2020 and subsequently recorded the fifth highest number of cases in Nigeria, most in the capital city Ibadan. We aimed to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that were circulating in Ibadan between August 2021 and August 2022 and to assess the utility of healthcare worker (HCW)-associated infections for endemic COVID-19 surveillance.
methodsFollowing ethical approval, SARS-CoV-2 real-time quantitative polymerase chain reaction (RT-qPCR)-confirmed samples were reverse-transcribed and sequenced on an Illumina MiSeq using ARTIC SARS-CoV-2 RT-PCR and sequencing protocols. Genomes were assembled using the nf-core/viralrecon pipeline. Quality control, phylogenetic, analysis, and variant identification were performed using publicly available software implemented in a custom Nextflow pipeline. Biodata and relevant clinical information were obtained from electronic case investigation forms.
resultsWe analyzed 258 samples with minimum non-N coverage of 70% and identified 12 SARS-CoV-2 lineages and 7 clades, all but one aligning with global lineages. Lineages BA.1 (22%) and BA.1.1 (48%) were the most common. Delta lineage predominated from August to September 2021, and was replaced by Omicron lineage from December 2021. Samples from HCWs (n = 60; 23%) accounted for a third (4 of 12) of all major lineages observed.
conclusionsWe contributed 258 genomes from Oyo State to the GSAID repository and identified Delta and Omicron lineages circulating in Ibadan, in temporal alignment with global circulating lineages. As clinical testing declines HCWs are useful sentinels for genomic epidemiology capturing much of the diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.